Release date: 2017-04-26
Cancer is a problem that humans have not yet overcome, and has been plaguing millions of families. Today, the world's first cancer vaccine will enter clinical trials, which brings new hope to cancer patients.
The University of Connecticut Health Center (UConn Health) has launched a recruitment program to conduct the world's first personalized genomics-driven ovarian cancer vaccine clinical trial to prevent ovarian cancer recurrence in women diagnosed late.
Ovarian cancer is one of the most deadly cancers, and only women can suffer, and the probability of recurrence is very high. Moreover, there are currently no early screening tests for ovarian cancer and no effective long-term treatment. The vast majority of women die within five years of diagnosis.
The "Oncoimmunome" vaccine for this clinical trial is considered to be extremely groundbreaking:
Each vaccine is created based on a DNA sample of the patient's cancerous cells and healthy cells, which is equivalent to being tailored to the patient. In about two weeks, scientists sequenced and cross-referenced whole DNA from two sources to determine the most important genetic differences.
OncoImmunome works by enhancing the patient's immune response so that it can destroy the surface of ovarian cancer cells. The US Food and Drug Administration (FDA) has approved human clinical trials of the vaccine. According to research published by the FDA, OncoImmunome effectively inhibits cancer progression in animal models.
The new clinical trial will first select 15 women with stage III or IV initial diagnosis or first recurrence of ovarian cancer, and pay close attention for two years at the time of the highest risk of recurrence.
Clinical trial candidates will first undergo a traditional surgery, and their tumor samples will be collected for vaccine production, and then they will undergo standard chemotherapy. If there is no tumor in their body after traditional treatment, these women receive a personal vaccination once a month for six months. In addition, researchers collect their blood every month and assess the immune response.
The clinical trial will be led by Dr. Susan Tannenbaum, head of the Department of Hematology and Oncology at UConn Health Carole and Ray Neag Comprehensive Cancer Center. Dr. Molly Brewer, Director of Obstetrics and Gynecology, and APRN Karen Metersky are also involved.
“This moment is finally here, we are very happy,†said Dr. Pramod K. Srivastava, vaccine inventor and immunotherapist, who is the director of the UConn Health Neag Comprehensive Cancer Center.
"We hope that this vaccine will make up for the huge gap in treatment options for patients with ovarian cancer and bring long-term solutions and treatments for this desperate disease. Since this test is the first in the world, there will be With a lot of variables, we hope to pass through this research on issues we are not aware of," Dr. Srivastava added.
Researchers use women's own DNA to build each ovarian cancer vaccine
According to Dr. Srivastava, this immunotherapy trial may lay the foundation for the development of genome-driven personalized cancer vaccines similar to other major cancers such as prostate cancer, bladder cancer, stomach cancer, colon cancer, etc.
Source: DeepTech Deep Technology (Public Number: mit-tr)
Sodium Erythorbate,Sodium Erythorbate Powder,Food Additives Sodium Erythorbate,Antioxidant Sodium Erythorbate
SHANDONG BAISHENG BIOTECHNOLOGY CO., LTD , https://www.baishengbioproducts.com